fr   en
Clinical Studies

Browse by date
Or search by keyword
Date: 2010-08-06
Phase: II
Anouncement: Launch
Biotech: Clavis Pharma (Norway)
Product: CP-4126 (lipid-conjugated derivative of gemcitabine, developed using Clavis' lipid vector technology)
Disease: pancreatic cancer
Other: Clavis Pharma and its partner Clovis Oncology, Inc. announce that the first two patients have been recruited into a Phase II clinical study comparing CP-4126 with gemcitabine in the treatment of patients with pancreatic cancer.
The trial is being conducted by Clovis Oncology as part of the $380 million partnership agreement signed with Clavis Pharma in November 2009. Under the terms of that agreement, Clovis is responsible for development and commercialization of CP-4126 in the US, EU and certain rest of world countries.

The Phase II trial is an international, randomised, controlled study in patients newly diagnosed with advanced, metastatic (stage 4) pancreatic cancer. The trial will enrol approximately 250 patients, across 80 centers around the world, randomised equally between the CP-4126 and gemcitabine arms. Eligible patients will have received no prior chemotherapy for advanced disease and must have metastasis biopsies available for analysis. This is the first randomized trial in pancreatic cancer to require tumour biopsies as an entry criterion, and will allow clinical outcomes to be correlated with specific molecular features of each patient's tumour.

The study will measure overall survival in prospectively-defined hENT1-low patients as the primary endpoint. Expression of hENT1 in metastatic tumour tissue will be measured during the trial and patients categorised into hENT1-high or hENT1-low groups prior to final analysis. The study is designed to show a statistically significant improvement in survival in patients with hENT1 low expression in CP-4126 compared to patients on gemcitabine.
Clovis Oncology anticipates that recruitment of this Phase II study will complete in 2011 and that it will report results from the trial in 2012.

In parallel, Clovis Oncology has entered into an agreement with Ventana Medical Systems, Inc. for the development of a companion diagnostic test to measure hENT1-levels in pancreatic tumours and classify hENT1 low patients.